Efficiency of Imatinib Treatment After 10 Years of Treatment in Patients With Gastrointestinal Stromal Tumours (GIST) (Gist-Ten)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT05009927|
Recruitment Status : Recruiting
First Posted : August 18, 2021
Last Update Posted : March 15, 2022
This is a 2 arms study concerning patients under imatinib treatment for at least 10 years of treatment with locally advanced/metastatic GIST.
In the first arm, patients will discontinue Imatinib treatment. This arm will allow to determine if the re-introduction of Imatinib at relapse is still an efficient treatment for the control of disease.
In the second arm, patients will continue Imatinib treatment, allowing to determine if the continuation of this treatment is efficient for disease control, by the rate of non-progression disease.
|Condition or disease||Intervention/treatment||Phase|
|Metastatic Gastrointestinal Stromal Tumor (GIST) C-KIT Mutation Advanced Gastrointestinal Stromal Tumor (GIST)||Drug: Imatinib tablets||Phase 2|
Gastrointestinal stromal tumors (GISTs) arise from mesenchymal stem cells which also give rise to the interstitial cells of Cajal within the GI tract. A large majority of GIST tumors harbour activating mutations in the proto-oncogenes KIT and/or PDGFRA, both coding cell-surface cytokine receptors with tyrosine-protein kinase activity.
Imatinib mesilate (Glivec®, Novartis Pharma SAS) is a selective tyrosine kinase inhibitor, leading to inhibition of KIT and PDGFRA signalling pathways. The introduction of imatinib has revolutionised the therapeutic management of GIST patients and has provided an unprecedented demonstration of the clinical benefit of a targeted therapy for patients with advanced/metastatic solid tumors.
Several studies have investigated the optimal duration of imatinib treatment in the advanced phase. The BFR14 trial demonstrated that 31% of advanced GIST patients treated with continuous imatinib beyond 1 year had documented disease progression compared to 81% in the interrupted imatinib group (p<0.0001). The authors concluded that treatment interruption resulted in rapid progression in most patients with advanced GIST and therefore should not be recommended in standard practice unless the patient experienced significant toxicity or disease progression. An update of the BFR14 trial at a median follow-up of 37 months showed that 91% of patients in the interrupted arm versus 62% in the continuous arm experienced progressive disease (p<0.0001). Majority (92%) of patients in the interrupted arm achieved tumor control once they recommenced imatinib after first progression. Ray-Coquard et al. reported that stopping imatinib after 5 years resulted in a higher rate of disease progression than imatinib maintenance in patients with advanced GIST responding to or stabilised by imatinib.
However, whether lifelong imatinib treatment duration is mandatory in metastatic GIST patients remains unclear. It is not known whether a cytostatic treatment of 10 years or longer is sufficient to inhibit definitively GIST cancer cells proliferation even after the interruption of the kinase inhibitor. This question has broad implications for all targeted therapies.
The aim of the present study is to address this question rigorously in a randomized setting. The investigators therefore want to determine whether prolonged use of imatinib beyond 10 years is needed to reduce the risk of GIST recurrence and to improve overall survival. For patients with imatinib interruption after at least 10 years of treatment, the investigators want to determine if imatinib rechallenge is efficient for treating recurrence. Therefore, the investigators design an open-label, randomized, multicenter phase II study to determine the clinical impact of maintaining imatinib treatment beyond 10 years in patients with locally advanced/metastatic GIST.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||50 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Randomized, Multicentre, Phase II Study Evaluating the Interest of Imatinib Treatment Maintenance or Interruption After at Least 10 Years of Treatment in Patients With Locally Advanced/Metastatic Gastrointestinal Stromal Tumors (GISTs)|
|Actual Study Start Date :||January 3, 2022|
|Estimated Primary Completion Date :||April 2022|
|Estimated Study Completion Date :||October 2024|
Experimental: Imatinib interruption
Immediate interruption of imatinib until progressive disease. In case of 1st relapse, imatinib will be reintroduced at 400mg/d and further increased at 800mg/d in case of 2nd relapse after re-introduction.
Drug: Imatinib tablets
Other Name: Glivec
No Intervention: Imatinib maintenancce
Maintenance of imatinib at the last dose routinely taken by the patient in the 10-year period prior to randomization (either 300 or 400 mg once daily). In case of progressive disease imatinib will be increased up to 800mg/day.
- Progression-free-rate at 6 months (PFR 6m) [ Time Frame: 6 months after randomization ]Defined as the rate of patients with a non-progressive disease 6 months after randomization
- Progression-free-survival (PFS) [ Time Frame: 5 years (i.e. at the the time of last patient last visit) ]Time from the date of randomization to the date of the first documented progression, or date of death due to any cause. Patients with no event at the time of the analysis will be censored at the date of last available tumor assessment
- Overall Survival (OS) [ Time Frame: 5 years (i.e. at the the time of last patient last visit) ]the time from the date of randomization to the date of death due to any cause.
- Safety profile [ Time Frame: 5 years (i.e. at the the time of last patient last visit) ]The assessment of safety will be based mainly on the frequency of AE based on the Common Toxicity Criteria version 5
- Quality of Life (QoL) [ Time Frame: 5 years (i.e. at the the time of last patient last visit) ]QoL will be assessed using the European Organization for Research and Treatment of Cancer (EORTC) Quality of life Questionnaire (QLQ-C30).
- Progression-free survival rechallenge [ Time Frame: 5 years (i.e. at the the time of last patient last visit) ]the time from the date of imatinib reintroduction in the experimental arm to the date of subsequent progression, or date of death due to any cause. Patients with no event at the time of the analysis will be censored at the the date of last available tumor assessment.
- Objective Response Rate (ORR) after imatinib reintroduction [ Time Frame: 5 years (i.e. at the the time of last patient last visit) ]Defined as the proportion of patients with a best overall response of Partial Response (PR) or Complete Response (CR) after imatinib reintroduction
- Duration of response (DOR) [ Time Frame: 5 years (i.e. at the the time of last patient last visit) ]the time from the date of first objective response following the reintroduction of imatinib to the date of the first subsequent documented radiological progression or death and censored at the date of last available tumor assessment.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05009927
|Contact: Jean-Yves BLAY, Pr||+33 4 78 78 27 email@example.com|
|CHU Besançon||Not yet recruiting|
|Besançon, France, 25000|
|Contact: Elsa KALBACHER, MD 03.70.63.24.03 firstname.lastname@example.org|
|Principal Investigator: Elsa KALBACHER, MD|
|Sub-Investigator: Loïc CHAIGNEAU, MD|
|Sub-Investigator: Guillaume MEYNARD, MD|
|Bordeaux, France, 33076|
|Contact: Antoine ITALIANO A.Italiano@bordeaux.unicancer.fr|
|Principal Investigator: Antoine ITALIANO|
|Sub-Investigator: Maud TOULMONDE|
|Sub-Investigator: Kevin BOURCIER|
|Sub-Investigator: Sophie COUSIN|
|Centre Léon Bérard||Recruiting|
|Lyon, France, 69373|
|Contact: Jean-Yves BLAY, PhD|
|Contact 04 78 78 27 57 email@example.com|
|Principal Investigator: Jean-Yves BLAY, PhD|
|Sub-Investigator: Mehdi BRAHMI|
|Sub-Investigator: Armelle DUFRESNE|
|Sub-Investigator: Isabelle RAY-COQUARD|
|Institut Paoli Calmettes||Not yet recruiting|
|Marseille, France, 13273|
|Contact: François BERTUCCI, PhD firstname.lastname@example.org|
|Principal Investigator: François BERTUCCI, PhD|
|Sub-Investigator: Audrey MONNEUR|
|Sub-Investigator: Elika LOIR|
|Sub-Investigator: Simon LAUNAY|
|Sub-Investigator: Frédéric VIRET|
|Sub-Investigator: Brice CHANEZ|
|Sub-Investigator: Delphine LOUVEL PERROT|
|Institut Curie||Not yet recruiting|
|Paris, France, 75005|
|Contact: Sophie PIPERNO NEUMANN email@example.com|
|Principal Investigator: Sophie PIPERNO NEUMANN|
|CHU de Reims||Not yet recruiting|
|Reims, France, 51100|
|Contact: Olivier BOUCHE, PhD|
|Principal Investigator: Olivier BOUCHE, PhD|
|Sub-Investigator: Mathilde BRASSEUR, MD|
|Sub-Investigator: Damien BOTSEN, MD|
|Centre Eugène Marquis||Not yet recruiting|
|Rennes, France, 35042|
|Sub-Investigator: Christophe PERRIN, MD|
|Principal Investigator: Marc PRACHT, MD|
|Sub-Investigator: Angélique BRUNOT, MD|
|Sub-Investigator: Astrid LIEVRE, PhD|
|Sub-Investigator: Eugénie RIGAULT, MD|
|Sub-Investigator: Thomas GRAINVILLE, MD|
|Sub-Investigator: Anne-Sophie MOUSSADDAQ, MD|
|Institut de Cancérologie de l'Ouest - Site Réné Gauducheau||Not yet recruiting|
|Saint-Herblain, France, 44805|
|Contact: Emanuelle BOMPAS|
|Principal Investigator: Emanuelle BOMPAS|
|Sub-Investigator: Fréderic ROLLAND|
|Sub-Investigator: Damien VANSTEENE|
|Institut de Cancérologie Lucien NEUWIRTH||Not yet recruiting|
|Saint-Paul-en-Jarez, France, 42270|
|Contact: Olivier COLLARD, MD Olivier.COLLARD@icloire.fr|
|Principal Investigator: Olivier COLLARD, MD|
|Sub-Investigator: Cécile VASSAL, MD|
|Institut Claudius Regaud||Not yet recruiting|
|Toulouse, France, 31059|
|Contact: Valentin THIBAUD valentin.Thibaud@iuct-oncopole.fr|
|Principal Investigator: Valentin THIBAUD|
|Sub-Investigator: Iphigénie KORAKIS|
|Sub-Investigator: Christine CHEVREAU|
|Institut de Cancérologie de Lorraine||Not yet recruiting|
|Vandœuvre-lès-Nancy, France, 54519|
|Contact: Maria RIOS, MD|
|Principal Investigator: Maria RIOS, MD|
|Institut Goustave Roussy||Not yet recruiting|
|Villejuif, France, 94805|
|Contact: Axel LE CESNE, PhD 01 42 11 43 16 firstname.lastname@example.org|
|Principal Investigator: Axel LE CESNE, PhD|
|Sub-Investigator: Rastislav BAHLEDA, MD|
|Sub-Investigator: Olivier MIR, MD|
|Sub-Investigator: Benjamin VERRET, MD|
|Principal Investigator:||Jean-Yves BLAY, Pr||Centre Léon Bérard, Lyon|